Untitled

[laragrantt]

Get Started Today - Order (Fondaparinux) Arixtra Online & Enjoy Peace of Mind

Embark on a hassle-free journey to wellness! Order your (Fondaparinux) Arixtra online today for a stress-free experience. Enjoy the convenience of doorstep delivery, saving time and confirming peace of mind. Our reliable service guarantees prompt and discreet delivery, making your health a top priority. Get started on your path to well-being now!

[laragrantt]

fondaparinux sodium injection for the prevention of venous thromboembolism in patients undergoing surgery

Low-molecular-weight heparins are effective and safe to motivate their use for prevention of post-operative venous thromboembolism (VTE), and they are probably the dominating pharmacological principle in this respect (Geerts et al 2002). In the very beginning of the low-molecular-weight heparin era it was considered important to have a high factor Xa inhibitor activity which ideally should be higher than the IIa inhibitor activity, but over the years the discussion came to focus on the optimal balance between inhibiting factor Xa and factor IIa. It was therefore of great theoretical interest when selective Xa inhibitors were identified, because it was then possible to answer the question: is it possible to obtain a good prophylactic effect by focusing on just one of the factors in the coagulation system? The discussion alluded to above on the role of Xa inhibition in the infancy of low-molecular-weight heparins could thereby be further argumued. The aim of this paper is to summarize present-day knowledge on the prophylactic effect of fondaparinux, a purely synthetic selective indirect inhibitor of factor Xa, the first representative of a new class of antithrombotic substances (Cheng 2002; Hoppensteadt et al 2003; Nijkeuter and Huisman 2004).

[laragrantt]

Fondaparinux: Should It Be Studied in Patients with COVID-19 Disease?

Heparin-induced thrombocytopenia (HIT) has been recently described in patients with COVID-19 treated with UFH or LMWH. The cumulative incidence of detectable HIT antibodies was 12% at 25 days in 88 patients who received at least 5 days of UFH9 while elevated level of antiheparin-PF4 antibodies was observed in most patients treated with LMWH suggesting that HIT can contribute to the fatal outcome in COVID-19 patients in critical condition.

Only another case series of three patients11 was published suggesting that the diagnosis of HIT in COVID-19 patients could be underestimated. Clinicians must be aware of the possibility of HIT in patients with COVID-19 treated with UFH or LMWH since early diagnosis is crucial to properly treat this condition while a delayed recognition may contribute to poor outcomes.

[laragrantt]

Is Fondaparinux an Effective Alternative Anticoagulant in Patients With Heparin-Induced Thrombocytopenia Type II? A Case Report and Review of the Literature

Heparin-induced thrombocytopenia (HIT) type II is an acquired, transient, prothrombotic disorder and a life-threatening complication of unfractionated (UFH) and low-molecularweight heparin (LMWH) therapy presenting with thrombocytopenia and/or complicating venous or arterial thromboembolism that is associated with increased in vivo thrombin generation.[1,2] It is generally recognized that HIT can be divided into two types: HIT type I non-immune mediated HIT) and HIT type II (immune-mediated HIT).[3] For the remainder of this paper the term HIT indicates HIT type II. Heparin-induced thrombocytopenia is a clinicopathologic condition and adverse drug reaction caused by platelet-activating antibodies of IgG class which are directed against a molecular complex formed by heparin and platelet α-granule protein, platelet factor 4 (PF4).[4,5] Heparin-induced thrombocytopenia occurs in 3% to 5% and 0.5% of patients receiving UFH and LMWH, respectively.[6] In the absence of alternative anticoagulation, the risk of thrombosis is ~5% to 10% per day in the first few days after cessation of heparin[7] and mortality from HIT range from 18% to 50%.[3] Currently, direct thrombin inhibitors (argatroban, lepirudin) and danaparoid are approved agents as nonheparin anticoagulants for the prevention and treatment of HIT.

Although they are effective, all of this drugs have their limitations and adverse affects. The synthetic pentasaccharide fondaparinux, a subcutaneously administered indirect acting factor-Xa inhibitor, offers a new alternative for both prevention and treatment of HIT, especially where licensed drugs are not available. Here we report the successful use of fondaparinux in the treatment of a patient presenting with acuteon-chronic renal failure requiring hemodialysis and HIT associated with thrombosis (HITT). We also review the current role of fondaparinux in the treatment and prophylaxis of thrombosis in patients with HIT.

[laragrantt]

Effect of Fondaparinux on Coagulation Assays Results of College of American Pathologists Proficiency Testing

Fondaparinux is a synthetic factor Xa inhibitor based on the active site pentasaccharide of heparin. Based on 5 randomized double-blind trials, fondaparinux became the first synthetic factor Xa inhibitor to be approved for clinical use by the Food and Drug Administration specifically for thromboprophylaxis after orthopedic surgery.1–5 More recently, a number of studies have assessed its efficacy in nonorthopedic surgical and medical patients. Fondaparinux has been shown to be equally as effective and safe as dalteparin in high-risk patients undergoing abdominal surgery.6 In acutely ill medical patients, fondaparinux has daparinux slightly elevated the prothrombin time (PT) by 1 second and activated partial thromboplastin time (aPTT) by 5 to 6 seconds, using a single reagent–instrument combination.20 A recent study examined the effects of fondaparinux and direct thrombin inhibitors on coagulation testing. Using mostly Dade Behring reagents, the study found that fondaparinux affected protein S activity resulting in false elevations of protein S levels even at very low (0.2 g/mL) drug concentrations.21 Fondaparinux did not affect fibrinogen, protein C, antithrombin, plasminogen, von Willebrand factor, D-dimer, or factors II, IX, or X. To further assess the influence of fondaparinux on coagulation testing across a wide variety of reagents being used in the United States, we report the results of a College of Pathologists (CAP) proficiency test survey in which the laboratories were asked to perform PT, aPTT, fibrinogen, antithrombin, factor VIII, thrombin time, and anti– factor Xa assays in samples supplemented with different levels of fondaparinux.

[laragrantt]

Why take Fondaparinux

Fondaparinux is a medicine that will help your blood flow more easily. It can be used to treat blood clots and to prevent them from forming. This drug is sometimes called a blood thinner.

[laragrantt]

How does Arixtra work?

Blood clotting can be a problem when blood flow is disturbed in any way. Arixtra is an anticoagulant: it prevents the blood from coagulating (clotting). The active ingredient in Arixtra, fondaparinux sodium, stops one of the substances (factors) that are involved in the clotting of blood, factor Xa. When this is blocked, no thrombin (another factor) can be produced, and no clot can be formed. By using Arixtra after surgery, the risk of a blood clot forming is greatly reduced. By reducing blood clots, Arixtra can also help the flow of blood to the heart to be maintained in patients with angina or who are having a heart attack.